Antineoplastic Agents, Alkylating

"Antineoplastic Agents, Alkylating" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)

Descriptor ID	D018906
MeSH Number(s)	D27.505.519.124.035 D27.505.954.248.150 D27.888.569.035.035
Concept/Terms	Antineoplastic Agents, Alkylating Antineoplastic Agents, Alkylating Alkylating Antineoplastic Agents Alkylating Antineoplastic Drugs Alkylating Antineoplastics Antineoplastic Alkylating Agents Antineoplastic Drugs, Alkylating Antineoplastics, Alkylating Alkylating Agents, Antineoplastic Alkylating Drugs, Antineoplastic Antineoplastic Alkylating Drugs Drugs, Antineoplastic Alkylating

Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Alkylating".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Alkylating Agents [D27.505.519.124]
Antineoplastic Agents, Alkylating [D27.505.519.124.035]
Therapeutic Uses [D27.505.954]
Antineoplastic Agents [D27.505.954.248]
Antineoplastic Agents, Alkylating [D27.505.954.248.150]
Toxic Actions [D27.888]
Noxae [D27.888.569]
Alkylating Agents [D27.888.569.035]
Antineoplastic Agents, Alkylating [D27.888.569.035.035]

Below are MeSH descriptors whose meaning is related to "Antineoplastic Agents, Alkylating".

Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Alkylating".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antineoplastic Agents, Alkylating" by people in this website by year, and whether "Antineoplastic Agents, Alkylating" was a major or minor topic of these publications.

Bar chart showing 16 publications over 9 distinct years, with a maximum of 3 publications in 2007 and 2014 and 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	1	0	1
2004	1	0	1
2005	2	0	2
2007	1	2	3
2014	0	3	3
2017	1	2	3
2019	0	1	1
2021	0	1	1
2022	0	1	1

Below are the most recent publications written about "Antineoplastic Agents, Alkylating" by people in Profiles.

Hao Q, Huang Z, Li Q, Liu D, Wang P, Wang K, Li J, Cao W, Deng W, Wu K, Su R, Liu Z, Vadgama J, Wu Y. A Novel Metabolic Reprogramming Strategy for the Treatment of Diabetes-Associated Breast Cancer. Adv Sci (Weinh). 2022 02; 9(6):e2102303.

View in: PubMed
Awah CU, Winter J, Mazdoom CM, Ogunwobi OO. NSUN6, an RNA methyltransferase of 5-mC controls glioblastoma response to temozolomide (TMZ) via NELFB and RPS6KB2 interaction. Cancer Biol Ther. 2021 12 02; 22(10-12):587-597.

View in: PubMed
Xiao G, Lundine D, Annor GK, Canar J, Ellison V, Polotskaia A, Donabedian PL, Reiner T, Khramtsova GF, Olopade OI, Mazo A, Bargonetti J. Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer. Cancer Res. 2020 02 01; 80(3):394-405.

View in: PubMed
Cai YS, Sarotti AM, G?ndisch D, Kondratyuk TP, Pezzuto JM, Turkson J, Cao S. Heliotropiumides A and B, new phenolamides with N-carbamoyl putrescine moiety from Heliotropium foertherianum collected in Hawaii and their biological activities. Bioorg Med Chem Lett. 2017 10 15; 27(20):4630-4634.

View in: PubMed
Chemaitilly W, Li Z, Krasin MJ, Brooke RJ, Wilson CL, Green DM, Klosky JL, Barnes N, Clark KL, Farr JB, Fernandez-Pineda I, Bishop MW, Metzger M, Pui CH, Kaste SC, Ness KK, Srivastava DK, Robison LL, Hudson MM, Yasui Y, Sklar CA. Premature Ovarian Insufficiency in Childhood Cancer Survivors: A Report From the St. Jude Lifetime Cohort. J Clin Endocrinol Metab. 2017 07 01; 102(7):2242-2250.

View in: PubMed
Kotzur T, Benavides-Garcia R, Mecklenburg J, Sanchez JR, Reilly M, Hermann BP. Granulocyte colony-stimulating factor (G-CSF) promotes spermatogenic regeneration from surviving spermatogonia after high-dose alkylating chemotherapy. Reprod Biol Endocrinol. 2017 Jan 11; 15(1):7.

View in: PubMed
Parra K, Valenzuela P, Lerma N, Gallegos A, Reza LC, Rodriguez G, Emmenegger U, Di Desidero T, Bocci G, Felder MS, Manciu M, Kirken RA, Francia G. Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth. Br J Cancer. 2017 01; 116(3):324-334.

View in: PubMed
Benavides-Garcia R, Joachim R, Pina NA, Mutoji KN, Reilly MA, Hermann BP. Granulocyte colony-stimulating factor prevents loss of spermatogenesis after sterilizing busulfan chemotherapy. Fertil Steril. 2015 Jan; 103(1):270-80.e8.

View in: PubMed
Wu J, Li QQ, Zhou H, Lu Y, Li JM, Ma Y, Wang L, Fu T, Gong X, Weintraub M, Wu S, Ding H. Selective tumor cell killing by triptolide in p53 wild-type and p53 mutant ovarian carcinomas. Med Oncol. 2014 Jul; 31(7):14.

View in: PubMed
Lammers PE, Shyr Y, Li CI, Hutchison AS, Sandler A, Carbone DP, Johnson DH, Keedy VL, Horn L. Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer. J Thorac Oncol. 2014 Apr; 9(4):559-62.

View in: PubMed

People

Explore

Similar Concepts

Top Journals